CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth

Shares of Champions Oncology, Inc. CSBR have lost 1.8% since the company reported its earnings for the quarter ended July 31, 2026. This compares with the S&P 500 Index's 0.2% rise over the same time frame. Over the past month, the stock has lost 2.2% compared with the S&P 500's 1.3% decline.

Champions Oncology reported first-quarter fiscal 2027 revenues of $15.2 million, up 8.8% from $13.9 million a year earlier. The GAAP net loss narrowed to $426,000 from $466,000, while loss per share remained unchanged at 3 cents. Adjusted earnings per share increased to 5 cents from 1 cent.

CSBR operates in one reportable oncology-services segment, but disaggregates revenues by offering. Pharmacology services revenues rose 6.9% to $14.2 million from $13.2 million, while Translational Oncology Solutions (TOS) data-license revenues jumped 187.1% to $893,000 from $311,000. Other TOS revenues declined 59.7% to $183,000 from $454,000.

Oncology services margin improved to 51% from 43% in the prior-year quarter. Cost of oncology revenues declined 5.8% to $7.5 million despite higher revenues, helping adjusted EBITDA rise to $671,000 from $59,000. Total costs and operating expenses increased 7.7% to $15.6 million.

Champions Oncology used $492,000 of cash in operating activities, against $600,000 of cash generated a year earlier. The company ended July with $4.4 million in cash. Accounts receivable, net, stood at $13.6 million, while deferred revenues increased to $9.6 million from $8.8 million as of April 30. Management said that cash on hand and expected operating cash flows should be sufficient to fund operations through at least September 2027.

Champions Oncology, Inc. price-consensus-eps-surprise-chart | Champions Oncology, Inc. Quote

CEO Robert Brainin said that improved study execution and conversion in the core research-services business supported revenue growth and margin expansion. Management also pointed to increased commercial activity around Champions Oncology's data offerings, reflecting the broader customer base developed over the past year. Data-license revenues in the quarter exceeded the amount generated during all of fiscal 2026, although management cautioned that contract timing can make quarterly data revenues uneven.

Revenue growth was primarily driven by higher sales and stronger conversion of contracted pharmacology work into recognized revenue, along with increased data licensing. Margin improvement reflected lower outsourced laboratory-service costs, particularly third-party radiolabeling work, partly offset by higher royalty costs associated with increased revenues.

Higher investment spending remained a counterweight. Research and development expenses increased 12.6% to $2.3 million, primarily because of higher share-based compensation related to Corellia. Sales and marketing expense surged 66.6% to $3.1 million as CSBR expanded its commercial organization to support research services and data licensing. General and administrative expenses rose 4% to $2.7 million.

Champions Oncology did not provide formal revenue or earnings guidance. Management said that sales and marketing expenses are expected to remain elevated as the company continues investing in commercial capabilities. It also emphasized continued revenue growth, expense discipline and converting growth into improved profitability.

Champions Oncology continued shifting strategic focus and investment away from flow cytometry and its Lumin SaaS offering, contributing to the decline in Other TOS revenues.

Meanwhile, discussions continued with venture groups and potential pharmaceutical partners regarding outside funding or a licensing partnership for Corellia, although management did not provide a timetable for an outcome.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Champions Oncology, Inc. (CSBR) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).